ELEV Elevation Oncology Inc.: Company Book Value

ELEV (elevationoncology.com) - company brandmark

Elevation Oncology (ELEV) relies on external contractors for molecule creation and testing, creating a heavy dependence on third-party timelines. The business faces intense pressure from industry behemoths and the risk of funding shortages, with the metric standing at 0.05. Anticipation of Phase 1 trial data against tumors drives the price action reflected in this chart for the shares.

ELEV Elevation Oncology, Inc. Book Capitalization (07/04/2022 - 08/02/2025)

Financial and market metric breakdowns for Elevation Oncology, Inc. (ELEV)

- price and consensus price forecast:
Market Price elevationoncology.com|ELEV - Consensus Target
- market capitalization data:
Market Value Elevation Oncology Inc.|ELEV - Enterprise Value
- book capitalization data:
Accounting Value per Share Elevation Oncology|ELEV - Book Capitalization|Market Capitalization to Book Value Ratio elevationoncology.com|ELEV - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Ratio Elevation Oncology|ELEV - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Elevation Oncology Inc.|ELEV - Company Aggregate Debts|Debts to Book Value Elevation Oncology Inc.|ELEV - Company Long-Term Debt|Company Short-Term Loans and Borrowings Elevation Oncology
Summary company analysis:elevationoncology.com - ELEV
Mass-produced product of Elevation Oncology

Elevation Oncology is strengthening its technological advantage through the robotization of screening and the automation of clinical trial data analysis. By analyzing the company's book capitalization trend, an investor can observe the dynamics of net assets minus liabilities, which objectively determines the issuer's financial stability and protection against bankruptcy, reflecting the market consensus regarding the predictability of equity growth over the long term.

Competitors of Elevation Oncology

BeiGene Oncology (ONC) - Total Stockholders' Equity|Halozyme Therapeutics (HALO) - Company Net Assets|revmed.com (RVMD) - Company Book Value|Book Capitalization AAPG|Company Net Assets CG Oncology Inc|Book Capitalization URGN|Book Capitalization BCAX (Bicara Corp)|PSNL - Company Book Value|Accounting Capitalization erasca.com ERAS|DCTH: Book Capitalization|YMAB - Company Net Assets|Book Capitalization AURA|CADL (Candel Therapeutics, Inc.) - Total Stockholders' Equity|ARAY - Company Book Value|Accounting Value of Company SELLAS Life Sciences Group Inc. (SLS)|Actuate Therapeutics (ACTU) - Company Net Assets|Accounting Value of Company Citius Oncology Inc. (CTOR)|TuHURA Biosciences - Book Capitalization|TARA - Company Net Assets|Fate Therapeutics, Inc. - Company Net Assets|WHWK: Book Capitalization|Company Book Value tscan.com TCRX|Champions Oncology, Inc. (CSBR) - Accounting Value of Company|Book Capitalization XBIT (XBiotech Inc)|Total Stockholders' Equity CEL-SCI Corp|OS Therapies Incorporated - Book Capitalization|Total Stockholders' Equity RADX (Radiopharm Theranostics Ltd)|Company Book Value Artiva Biotherapeutics ARTV|Company Book Value Adlai Nortye Ltd ANL|VERU (Veru Pharma) - Book Capitalization|Tempest Therapeutics Corp (TPST) - Total Stockholders' Equity|xiliotx.com (XLO) - Company Net Assets|Renovaro (RENB) - Company Book Value|MURA (Mural Oncology PLC) - Book Capitalization|Book Capitalization Kairos Pharma Inc (KAPA)|Company Net Assets OnKure Therapeutics Inc|Total Net Assets w2.cytomed.sg (GDTC)|Book Capitalization CRIS|Apollomics Inc. - Book Valuation of Business|THAR (Tharimmune) - Company Book Value|ADVB: Total Stockholders' Equity|Company Book Value Genprex, Inc|Accounting Capitalization Calidi Biotherapeutics, Inc.|SBFM - Company Net Assets|Accounting Value of Company XBIO|Salarius Pharmaceuticals, Inc. - Company Book Value|Total Stockholders' Equity PPBT (Purple Biotech Ltd)|AONC - Company Book Value|Accounting Capitalization BeiGene Ltd BGNE|CKPT: Book Capitalization|ICAD: Company Net Assets|Company Book Value IKNA|NTBL (Notable Labs Ltd) - Total Stockholders' Equity|Company Book Value Viracta Therapeutics Inc.|Company Book Value MOR|NAYA Biosciences - Company Book Value|Total Stockholders' Equity ascentage.com (AAPGV)